Signal2026-07-07
ClinicalTrials.gov

[PHASE2] Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

Part of

Molecular Profiling In Endocrine Neoplasms